These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28664853)

  • 1. Reappraisal of the clinical effect of mepolizumab - Authors' reply.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A
    Lancet Respir Med; 2017 Jun; 5(6):e21. PubMed ID: 28664853
    [No Abstract]   [Full Text] [Related]  

  • 2. Reappraisal of the clinical effect of mepolizumab.
    Lipworth BJ; Jabbal S
    Lancet Respir Med; 2017 Jun; 5(6):e20. PubMed ID: 28664852
    [No Abstract]   [Full Text] [Related]  

  • 3. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
    Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
    Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
    Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients.
    Oldhoff JM; Darsow U; Werfel T; Bihari IC; Katzer K; Laifaoui J; Plötz S; Kapp A; Knol EF; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
    Int Arch Allergy Immunol; 2006; 141(3):290-4. PubMed ID: 16931891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
    Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab for Eosinophilic COPD.
    Shahlavi‑Monavvar P; Mobasher-Jannat A
    N Engl J Med; 2018 Feb; 378(7):681. PubMed ID: 29446292
    [No Abstract]   [Full Text] [Related]  

  • 12. Mepolizumab for Eosinophilic COPD.
    Xia Y; Li W; Shen H
    N Engl J Med; 2018 Feb; 378(7):680-1. PubMed ID: 29446291
    [No Abstract]   [Full Text] [Related]  

  • 13. Mepolizumab for Eosinophilic COPD.
    Sciurba FC; Bradford ES; Pavord ID
    N Engl J Med; 2018 Feb; 378(7):681-683. PubMed ID: 29443666
    [No Abstract]   [Full Text] [Related]  

  • 14. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
    Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
    Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab treatment for asthma.
    Robinson DS
    Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.
    Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S
    Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe eosinophilic asthma and mepolizumab.
    Walsh GM
    Lancet Respir Med; 2016 Jul; 4(7):528-529. PubMed ID: 27177492
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.